Zepbound vs Retatrutide: Switching Between Them

How Zepbound and Retatrutide Compare on Paper

These two drugs share the GLP-1 receptor as a target but differ in how many additional receptors they engage. Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly, FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Retatrutide, also developed by Eli Lilly, adds a third target: the glucagon receptor. This triple-receptor mechanism is designed to increase energy expenditure through glucagon-mediated thermogenesis while preserving the appetite suppression driven by GLP-1 and the insulin-sensitizing effects of GIP [1].

No direct head-to-head trial comparing tirzepatide and retatrutide has been published or registered in ClinicalTrials.gov as of May 2026. All comparisons between these drugs rely on cross-trial analysis, which carries inherent limitations: different patient populations, different trial durations, and different dose-titration schedules. Clinicians making treatment decisions should weigh these caveats heavily.

The pharmacological distinction matters for switching. Tirzepatide binds two incretin receptors. Retatrutide binds three. A patient moving from Zepbound to retatrutide would be introducing glucagon receptor agonism for the first time, which may affect hepatic glucose output, lipid metabolism, and resting energy expenditure in ways that dual agonism does not [2].

Weight Loss Data: SURMOUNT-1 vs the Phase 2 Retatrutide Trial

The headline numbers favor retatrutide, but the trial designs are not equivalent. SURMOUNT-1 (N=2,539) randomized adults with obesity (BMI ≥30, or ≥27 with a comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo for 72 weeks. The top-dose group lost 20.9% of body weight versus 3.1% in the placebo arm [1]. That result made tirzepatide the most effective approved anti-obesity medication at the time of publication.

The phase 2 retatrutide trial (N=338) tested doses from 1 mg to 12 mg over 48 weeks in adults with obesity. The 12 mg group achieved 24.2% mean body-weight loss [2]. Impressive. But this was a smaller trial with a shorter duration. Phase 2 studies are designed to find the right dose, not to confirm efficacy with the statistical rigor of a phase 3 program.

A few specific differences deserve attention. SURMOUNT-1 enrolled a broader population, including participants with type 2 diabetes excluded from the retatrutide phase 2 obesity cohort. The retatrutide trial used a more aggressive dose escalation. And 48 weeks is 24 weeks shorter than 72 weeks, meaning the retatrutide weight-loss curve may not have plateaued [2].

Dr. Ania Jastreboff, lead author of the retatrutide phase 2 paper and associate professor at Yale School of Medicine, noted: "These results support further development of retatrutide for the treatment of obesity" [2]. The phase 3 TRIUMPH program is testing whether these early results hold up in larger, longer studies.

The Glucagon Receptor: What Makes Retatrutide Different

Retatrutide's third receptor target is the glucagon receptor, and this addition changes the metabolic profile of the drug in meaningful ways. Glucagon promotes hepatic glycogenolysis and gluconeogenesis. It increases energy expenditure. It also accelerates hepatic lipid oxidation, which is why researchers are studying retatrutide in metabolic dysfunction-associated steatotic liver disease (MASLD) [3].

This is not simply an additive effect. Glucagon receptor activation can raise blood glucose, a counterproductive result in patients with type 2 diabetes. The GLP-1 and GIP components of retatrutide appear to offset this effect in clinical testing, but the balance may shift depending on the patient's metabolic baseline [2].

For patients switching from Zepbound, the introduction of glucagon receptor agonism represents a qualitatively new pharmacological exposure. This is not like switching between two SSRIs with the same mechanism. It is more analogous to adding a new drug class, with new potential benefits and new monitoring requirements.

Animal studies suggest glucagon receptor agonism may contribute to lean mass preservation during weight loss, though this has not been confirmed in human trials of retatrutide specifically [4]. The phase 3 program may provide body composition data that clarify whether retatrutide offers advantages beyond scale weight.

Can You Actually Switch from Zepbound to Retatrutide?

The short answer: not through standard clinical channels in 2026. Retatrutide is not FDA-approved. It remains available only through clinical trials or, in some cases, compounding pharmacies operating in regulatory gray areas. The FDA's compounding guidance does not list retatrutide on the approved bulk substance list for 503B outsourcing facilities.

No medical society, including the Endocrine Society or the American Association of Clinical Endocrinology (AACE), has published switching guidelines between these two agents. The absence of such guidance reflects the investigational status of retatrutide and the lack of any clinical data on the transition itself.

If a clinician were to design a switching protocol based on pharmacological first principles, several considerations would apply: matching the GLP-1 component dose to minimize GI side effects during transition, introducing glucagon receptor agonism at the lowest available dose, monitoring hepatic enzymes and fasting glucose more frequently during the first 8 to 12 weeks, and maintaining the same caloric and exercise framework to isolate drug effects.

GI Tolerability: What to Expect During a Transition

Both drugs cause gastrointestinal side effects. This is the price of potent incretin receptor agonism. In SURMOUNT-1, nausea occurred in 24.6% of patients on tirzepatide 15 mg, diarrhea in 23.0%, and vomiting in 11.4% [1]. The retatrutide phase 2 trial reported nausea in 35.4% of the 12 mg group, diarrhea in 16.5%, and vomiting in 15.8% [2].

These rates are not directly comparable because the trials used different titration speeds. Slower titration generally reduces GI symptoms. But the overall signal is consistent: both drugs produce meaningful nausea rates, and switching between them will likely re-expose patients to an adaptation period.

A patient who has already titrated to a stable Zepbound dose has adapted their GI tract to GIP/GLP-1 agonism. Switching to retatrutide preserves that receptor exposure but adds glucagon. Whether the glucagon component independently worsens GI tolerance is unknown. Early data suggest that most GI effects of retatrutide are mediated by the GLP-1 component rather than the glucagon component [2], which would favor a smoother transition for patients already adapted to Zepbound.

Clinicians managing this switch should plan for a 4 to 8 week re-titration window with standard GI mitigation strategies: small frequent meals, adequate hydration, and temporary avoidance of high-fat foods. Anti-emetic use may be appropriate during the first 2 to 4 weeks at each new dose.

Efficacy Plateau and the Case for Switching

One clinical scenario where switching makes pharmacological sense is the weight-loss plateau. Patients on tirzepatide typically reach maximum weight loss between weeks 60 and 72 [1]. If a patient has plateaued on maximum-dose Zepbound and requires additional weight reduction for metabolic or surgical reasons, the addition of glucagon receptor agonism through retatrutide could theoretically provide incremental benefit.

This is speculative. No trial has enrolled patients who plateaued on tirzepatide and then switched to retatrutide. The SURMOUNT-3 trial studied tirzepatide after an intensive lifestyle intervention, not after another incretin drug [5]. And the retatrutide phase 3 program enrolls treatment-naive patients, not patients switching from approved GLP-1 receptor agonists.

The metabolic rationale rests on glucagon's ability to increase resting energy expenditure by 5 to 10% in pharmacological studies [4]. If a patient has hit a ceiling with appetite suppression alone, adding thermogenic activity could shift the energy balance equation. But this remains a hypothesis, not a proven strategy.

Cost, Access, and Practical Barriers

Zepbound carries a list price of approximately $1,060 per month in the United States, with manufacturer savings cards reducing out-of-pocket costs for commercially insured patients. Insurance coverage varies by plan, with prior authorization requirements common for obesity indications.

Retatrutide has no commercial price because it has no commercial product. Patients in clinical trials receive the drug at no cost but must meet strict inclusion criteria and commit to regular study visits. The phase 3 TRIUMPH program is actively enrolling at sites across the United States, Europe, and Asia.

Patients considering a switch should understand that moving from an approved drug to an investigational one means surrendering the certainty of continued access. If the trial ends, if the patient is randomized to placebo, or if retatrutide fails to win approval, the patient returns to square one. This is a non-trivial risk for someone who has achieved significant weight loss on Zepbound and depends on continued pharmacotherapy to maintain it.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity states: "Long-term pharmacotherapy is recommended for patients with obesity to maintain weight loss" [6]. Interrupting an effective therapy to switch to an unproven alternative runs counter to this principle unless the clinical rationale is strong.

What Phase 3 Data Will (and Won't) Tell Us

The TRIUMPH phase 3 program includes multiple trials evaluating retatrutide in obesity, type 2 diabetes, and MASLD. Results are expected between 2025 and 2027. These trials will establish whether the phase 2 weight-loss results replicate at scale, define the long-term safety profile, and provide the data needed for regulatory submission [2].

What phase 3 will not provide is a direct comparison with tirzepatide. No registered TRIUMPH trial uses Zepbound as an active comparator. This means that even after phase 3 results are available, the comparison between these drugs will remain indirect, relying on cross-trial inference rather than randomized head-to-head data.

For clinicians and patients waiting to make a switching decision, the practical implication is that the evidence base will improve but will not become definitive. A switching recommendation will require either a dedicated crossover study or accumulated real-world evidence from clinical practice after both drugs are commercially available.

Post-marketing observational data from registries and electronic health records may eventually fill this gap. The National Patient-Centered Clinical Research Network (PCORnet) has infrastructure to conduct such analyses, but these studies typically lag drug approval by 2 to 3 years.

Safety Monitoring If Switching Becomes Possible

Both tirzepatide and retatrutide carry boxed warnings (or, for retatrutide, anticipated warnings based on class effects) regarding medullary thyroid carcinoma risk in rodents. The clinical relevance in humans is uncertain, but a family history of MTC or MEN2 remains a contraindication for both agents [1][2].

Switching-specific safety concerns include:

The glucagon receptor's effect on hepatic glucose output. Patients with prediabetes or early type 2 diabetes may see transient fasting glucose elevations during the transition. Monitoring HbA1c and fasting glucose at baseline and at 4, 8, and 12 weeks post-switch is reasonable.

Cardiovascular parameters. Tirzepatide showed favorable effects on blood pressure and lipids in SURMOUNT-1, with systolic BP reductions of 6.2 to 7.4 mmHg across dose groups [1]. Retatrutide's cardiovascular profile in phase 2 was similar, with systolic BP reductions of 4.4 to 7.8 mmHg [2]. The transition between agents should not dramatically alter cardiovascular risk markers, but monitoring during the first 3 months is prudent.

Hepatic enzymes. Glucagon receptor agonism increases hepatic lipid oxidation, which may transiently raise ALT in patients with fatty liver disease. Phase 2 data from the retatrutide MASLD sub-study showed reductions in liver fat of up to 42.9% at 48 weeks [7], but early transaminase fluctuations occurred in some participants.

The recommended monitoring schedule for a hypothetical switch: baseline labs (comprehensive metabolic panel, lipid panel, HbA1c, ALT/AST), then repeat at weeks 4, 8, 12, and every 12 weeks thereafter until stable.